SciSparc Doses First Patient in Autism Treatment Trial

SciSparc Ltd. (Nasdaq: SPRC) has successfully dosed the first patient in its SCI-210 clinical trial for pediatric patients with Autism Spectrum Disorder (ASD). This is a significant milestone for the company as it evaluates its proprietary SCI-210 treatment, a combination of cannabidiol-rich oil (CBD) and CannAmide™ palmitoylethanolamide-based tablets in its quest to offer a safer and more effective treatment option for ASD.

On Monday, the company’s share price rose slightly in morning trading after the company announced that it had been granted a patent for its core technology, the combination of cannabinoids and n-acylethanolamines, by the Canadian Intellectual Property Office. The Patent covers the compositions and methods for potentiating therapeutic effects and/or reducing the side-effects of selected cannabinoids initially discovered in the cannabis plant.

SciSparc’s randomized, double-blind, placebo-controlled, cross-over clinical study will evaluate the safety, tolerability, and efficacy of SCI-210 in comparison to CBD monotherapy for the treatment of ASD. The study will span 20 weeks and enroll 60 children. Primary endpoints include the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire and the Clinical Global Impressions-Improvement (CGI-I) scale administered by healthcare professionals. The study will help to determine the effective therapeutic dosage.

Oz Adler, SciSparc’s Chief Executive Officer commented on the trial, “Dosing the first patient is always an exciting moment in any clinical trial. As we work to offer new hope to the patients, family members, and caretakers who are battling this disorder, we are excited to kick-off this next phase of development for SCI-210.

“We are thrilled to reach this milestone, which brings us one step closer to potentially offering a new beacon of hope for patients and families affected by ASD. We are grateful to the patients, Professor Meiri and his team involved in the clinical trial. This achievement represents a pivotal moment for SciSparc as we introduce SCI-210, an innovative cannabinoid-based treatment.”

About SciSparc Ltd. (Nasdaq: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI- 210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds oil-based products on the Marketplace.

Share This Article


About the Author

SciSparc Doses First Patient in Autism Treatment Trial

Catie Corcoran

Biotech Editor